Purity CAS 540737-29-9 Tofacitinib Citrate Pharmaceutical Intermediate Tofacitinib Citrate Powder Tofacitinib Citrate

• Powder: Yes
• Customized: Customized
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Adult
• State: Powder
• Purity: >99%
• Model NO.: Dsung-Tofacitinib Citrate
• Product Name: Tofacitinib Citrate
• Name: Tofacitinib Citrate Powder
• Appearance: White Solid Powder
• Color: White
• Grade: Pharmaceutical Grade
• Assay: HPLC 99%
• Application: Pharmaceutical
• Specific: COA
• Test Method: HPLC
• Shelf Life: 2 Years
• CAS No.: 540737-29-9
• Molecular Formula: C22h28n6o8
• MW: 504.49300
• Psa: 221.04000
• Logp: 504.19700
• Transport Package: Negotiable
• Specification: 99%
• Trademark: D-Sung
• Origin: Shaanxi
• Production Capacity: 10kg/Month

Product Description

Purity CAS 540737-29-9 Tofacitinib Citrate Pharmaceutical Intermediate Tofacitinib Citrate Powder Tofacitinib Citrate

Product Description

Product Details

Product Name	Tofacitinib Citrate
CAS No.	540737-29-9
Purity	99%
MW	504.49300
Appearance and shape	White solid powder

Tofacitinib citrate is an oral drug used for treating rheumatoid arthritis. It belongs to a class of drugs called Janus kinase (JAK) inhibitors. JAKs are enzymes (proteins) that regulate chemical signaling pathways that control biologic processes such as blood formation and the immune response that causes the pain, tenderness and swelling of inflammation. JAKs are found in many cells, especially stem cells in bones and joints. Inhibition of JAKs by tofacitinib prevents inflammation and tissue destruction that is associated with the inflammation of rheumatoid arthritis.

Application & Function

(1).Tofacitinib citrate is a king of drugs developed by the US pharmaceutical company for treating rheumatoid arthritis, for the treatment of methotrexate inadequate response or intolerance to severe active rheumatoid arthritis (RA) in adult patients. Tofacitinib citrate is approved for the treatment of methotrexate inadequate response or intolerance to severe active rheumatoid joints arthritis (RA) in adult patients.
(2). It can be used as monotherapy or in combination with methotrexate or other non-biological disease-modifying antirheumatic drugs (the DMARD) in combination. This medicine should not be in combination with biological DMARD or strong immunosuppressants (such as cyclosporine and azathioprine) . Tofacitinib citrate is approved by the daily dose of 2 times, each time 5mg. Seven clinical trials evaluated the safety and efficacy of Tofacitinib citrate in moderate to severe active RA in adult patients. In all tests, compared with patients receiving placebo, patients receiving Tofacitinib citrate treatment showed significant improvement in clinical response and physical function.abbreviated as NAD+ and NADH respectively.

Specification